156 results on '"Horneff, G."'
Search Results
2. AB1701 IS THERE A DIFFERENCE IN THE NUMBER OF INVOLVED ORGAN SYSTEMS BETWEEN JUVENILE DIFFUSE AND LIMITED SUBTYPE SYSTEMIC SCLEROSIS PATIENTS?
3. LBA0008 EFFECTIVENESS OF CANAKINUMAB FOR FIRST LINE STEROID FREE TREATMENT IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
4. POS0189 CANAKINUMAB AS 1ST OR 2ND BIOLOGIC IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – DATA FROM THE BiKeR REGISTRY
5. POS0757 OCCURRENCE OF UVEITIS AND FLARES IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS UPON TUMOUR NECROSIS FACTOR (TNF)- INHIBITORS
6. POS0119 VACCINATION RATE AND PROTECTION AGAINST VARICELLA AND ZOSTER THROUGH VZV VACCINATION IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS
7. POS0776 SAFETY AND EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS - UPDATES FROM THE BIKER REGISTRY
8. POS0758 PRESENCE OF NAILFOLD CAPILLARY CHANGES CORRELATES WITH MORE SEVERE ORGAN INVOLVEMENT IN JUVENILE SYSTEMIC SCLERODERMA. RESULTS OF THE JUVENILE SCLERODERMA INCEPTION COHORT.
9. POS0774 TNF-ALPHA INHIBITOR FIRST-LINE THERAPY OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN COMPARISON: DATA FROM THE GERMAN BIKER REGISTRY
10. OP0087 PHYSICAL ACTIVITY, SCREEN TIME AND HEALTH RELATED QUALITY OF LIFE AMONG ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
11. POS0770 DIFFERENCES IN CLINICAL PRESENTATION BETWEEN JUVENILE SYSTEMIC SCLEROSIS PATIENTS WITH DIFFUSE AND LIMITED SUBTYPE. RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT.
12. OP0211 TREAT-TO-TARGET IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS - A PROTOCOLS IN PAEDIATRIC RHEUMATOLOGY (PROKIND) STUDY
13. Unravelling the clinical heterogeneity of undefined recurrent fever over time in the European registries on Autoinflammation
14. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry
15. POS0277 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED LUNG DISEASE IN EUROPE
16. OP0164 SAFETY AND EFFICACY OF UPADACITINIB FOR PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: AN INTERIM ANALYSIS OF AN OPEN-LABEL, PHASE 1 TRIAL
17. OP0161 24 MONTH RESULTS ON EFFECTIVENESS AND SAFETY OF A COMPARATIVE STUDY OF TOCILIZUMAB VERSUS TUMOUR NECROSIS FACTOR INHIBITION IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
18. POS0751 PHARMACOKINETICS OF UPADACITINIB IN PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS
19. POS0139 DIFFUSE JUVENILE SYSTEMIC SCLEROSIS PATIENTS SHOW DISTINCT ORGAN INVOLVEMENT, ANTIBODY PATTERN AND HAVE SIGNIFICANTLY MORE SEVERE DISEASE IN THE LARGEST JSSC COHORT OF THE WORLD. RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT
20. OP0163 GOLIMUMAB FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS – AN UPDATE ON SAFETY AND EFFECTIVENESS FROM THE BIKER REGISTRY
21. POS0284 COVID-19 SYMPTOMS AND DISEASE COURSE IN GERMAN PEDIATRIC RHEUMATOLOGY PATIENTS REPORTED TO BIKER
22. POS0140 PATIENT AND PHYSICIAN REPORTED OUTCOMES OF JUVENILE SYSTEMIC SCLEROSIS PATIENTS SIGNIFICANTLY IMPROVE OVER 24 MONTHS OBSERVATION PERIOD IN THE JUVENILE SYSTEMIC SCLERODERMA INCEPTION COHORT
23. AB1446 TREATMENT PATTERNS IN A POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS POPULATION IN GERMANY; A RETROSPECTIVE OBSERVATIONAL HEALTH CLAIMS DATA STUDY
24. POS0141 APPLICATION OF CRISS SCORE, REVISED CRISS SCORE AND RCID SCORE IN PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS
25. POS1570 LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN FAMILIAL MEDITERRANEAN FEVER (FMF) – 36-MONTH DATA FROM THE RELIANCE REGISTRY
26. POS1573 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TRAPS (TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY
27. POS1558 LONG-TERM SAFETY OF CANAKINUMAB IN AUTOINFLAMMATORY PERIODIC FEVER SYNDROMES – 48-MONTH DATA FROM THE RELIANCE REGISTRY
28. OP0252 LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) – 4-YEARS DATA FROM THE RELIANCE REGISTRY
29. POS0287 TOFACITINIB IN JUVENILE IDIOPATHIC ARTHRITIS: FIRST YEAR EXPERIENCE
30. Verlauf der COVID-19-Pandemie bei pädiatrisch-rheumatologischen Patienten in Deutschland in den letzten drei Jahren
31. Anwendung von Belimumab zur Behandlung des juvenilen systemischen Lupus erythematodes in der klinischen Praxis - ein BIKER-Registerprojekt
32. Schutz vor Varizellen und Zoster durch VZV-Impfung bei Patienten mit juveniler idiopathischer Arthritis
33. Bakterielle Arthritis bei einer immunkompetenten Patientin durch Kocuria rhizophila
34. Auswirkungen der Coronavirus-Pandemie auf Patienten mit autoinflammatorischen periodischen Syndromen unter Canakinumab-Behandlung - Interimsergebnisse aus dem RELIANCE-Register
35. Diffuse juvenile systemic sclerosis patients show distinct organ involvement, antibody pattern and have significantly more severe disease in the largest jSSc cohort of the world. Results from the juvenile scleroderma inception cohort
36. Führt die Langzeitbehandlung mit Canakinumab bei autoinflammatorischen periodischen Fiebersyndromen vermehrt zu Infektionen? 48-Monats-Daten des RELIANCE-Registers
37. Behandlungsmuster in einer polyartikulären juvenilen idiopathischen Arthritis-Population in Deutschland: Eine retrospektive Beobachtungsstudie auf Basis von Krankenkassenabrechnungsdaten
38. Is decreased body mass index-2 z score or less correlating with an organ involvement pattern? Results from the juvenile scleroderma inception cohort
39. Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 24 months observation period in the juvenile systemic scleroderma inception cohort
40. 24-Monats-Daten zu Wirksamkeit und Sicherheit von Tocilizumab im Vergleich zu TNF Inhibitoren bei polyartikulärer juveniler idiopathischer Arthritis
41. Elternberichtete-Outcomes und Therapiezufriedenheit im ersten Behandlungsjahr bei JIA, SLE und JDM - Interimsergebnisse aus ProKind-Rheuma
42. Langzeitwirksamkeit von Canakinumab bei autoinflammatorischen periodischen Syndromen - Interimsanalyse des RELIANCE-Registers
43. Application of CRISS score, revised CRISS score and RCID score in patients with Juvenile systemic sclerosis
44. Tumor-Nekrose-Faktor-alpha-Inhibitor-Ersttherapien der Juvenilen idiopathischen Arthritis im Vergleich: Eine Datenanalyse aus dem BiKeR-Register
45. POS0172 DIFFUSE JUVENILE SYSTEMIC SCLEROSIS PATIENTS SHOW DISTINCT ORGAN INVOLVEMENT AND HAVE MORE SEVERE DISEASE IN THE LARGEST jSSc COHORT OF THE WORLD. RESULTS FROM THE THE JUVENILE SCLERODERMA INCEPTION COHORT. www.juvenile-scleroderma.com
46. AB1236 CLINICAL CHARACTERISTICS OF JUVENILE ONSET SYSTEMIC SCLEROSIS PATIENTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT COMPARED TO ADULT AGE JUVENILE-ONSET PATIENTS FROM EUSTAR. ARE THESE DIFFERENCES SUGGESTING RISK FOR MORTALITY?
47. POS1302 PATIENT AND PHYSICIAN REPORTED OUTCOMES OF JUVENILE SYSTEMIC SCLEROSIS PATIENTS SIGNIFICANTLY IMPROVE OVER 12 MONTHS OBSERVATION PERIOD IN THE JUVENILE SYSTEMIC SCLERODERMA INCEPTION COHORT. www.juvenile-scleroderma.com
48. OP0216 DEVELOPMENT, REFINEMENT AND WEIGHTING OF CANDIDATE CRITERIA FOR AXIAL DISEASE IN JUVENILE SPONDYLOARTHRITIS: AN INTERNATIONAL COLLABORATION
49. POS0170 EXPERIENCES WITH COVID-19 INFECTIONS IN GERMAN PEDIATRIC RHEUMATOLOGY CENTERS
50. POS0338 TRANSITION COMPETENCE IN YOUNG PEOPLE WITH JUVENILE IDIOPATHIC ARTHRITIS HAS IMPROVED OVER TIME
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.